ELVN - Company ID 0001672619
The table below shows Enliven Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$19.29M | -$24.13M | -$23.36M | -$20.84M | -$10.36M | -$13.02M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $42.53M | $1.43M | -$17.89M | -$31.00K | -$194.00K | $18.30M |
| Dividends paid | - | - | - | - |
Enliven Therapeutics, Inc. reported operating cash flow of -$70.30M for fiscal year 2025. That is up 3.9% from -$73.19M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$21.88M (FY 2019) to -$70.30M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $10.05M | $234.00K | $90.27M | $237.44M | $409.00K | $460.00K |